Risk of higher energy and laboratory animal procurement prices
First written in FY2024. 3 of 4 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「Nonclinical testing uses substantial amounts of energy in the housing of animals and the testing process. As energy prices have risen in recent years, utility costs at nonclinical testing facilities have been trending higher. In addition, supply and demand for some laboratory animals has tightened, and procurement prices have also been trending higher.」
The company reconfirms the risk of higher energy prices and laboratory animal procurement costs in nonclinical testing. - 2026-03-25RestatedOccurring Fact
「The continued rise in the price of laboratory animals since the COVID-19 pandemic has placed pressure on the research and development capacity of pharmaceutical companies and drug-discovery ventures.」
The company reconfirmed the cost-related risk that persistently rising laboratory animal prices are putting pressure on customers' research and development capacity. - FY2025-H1RestatedAnnual report
「The yen's rapid depreciation and high energy and raw material prices continued, and conditions remained uncertain.」
The company reconfirms that external cost risks related to higher energy and raw material prices continue. - FY2024First statedAnnual report
「Nonclinical testing uses substantial amounts of energy in the housing of animals and the testing process. As energy prices have risen in recent years, utility costs at nonclinical testing facilities have been trending higher. In addition, supply and demand for some laboratory animals has tightened, and procurement prices have also been trending higher. We formulate our business plans taking these trends into account, but an increase in prices beyond forecasts could have a material impact on the group's results.」
The company explicitly identifies energy consumption and utility costs inherent in nonclinical testing, as well as tight supply and demand and higher procurement prices for laboratory animals, as new cost risks.